Loading...
11 spironolactone COVID-19 controlled studies, 3 RCTs
https://c19early.org/spmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Cadegiani 77% 0.23 [0.08-0.66] recov. time 8 (n) 262 (n) Improvement, RR [CI] Treatment Control Cadegiani 83% 0.17 [0.06-0.51] recov. time 8 (n) 262 (n) Cadegiani 38% 0.62 [0.42-0.91] viral time 8 (n) 262 (n) Mareev (RCT) 11% 0.89 [0.65-1.22] no recov. 33 (n) 33 (n) CT1 Mareev (RCT) 39% 0.61 [0.14-0.97] no recov. 14/24 20/21 CT1 Mareev (RCT) 8% 0.92 [0.77-1.09] hosp. time 33 (n) 33 (n) CT1 Mareev (RCT) 87% 0.13 [0.01-2.25] viral+ 0/17 3/13 CT1 Ersoy (ICU) 46% 0.54 [0.36-0.81] death 14/30 26/30 ICU patients Davarpanah 78% 0.22 [0.08-0.55] hosp. 6/103 23/103 CT1 Davarpanah 64% 0.36 [0.21-0.60] recov. time 103 (n) 103 (n) CT1 Abbasi (SB RCT) 55% 0.45 [0.18-1.13] death 5/51 19/87 Abbasi (SB RCT) 34% 0.66 [0.30-1.48] ventilation 7/51 18/87 Abbasi (SB RCT) 19% 0.81 [0.42-1.59] ICU 10/51 21/87 Abbasi (SB RCT) 47% 0.53 [0.39-0.72] no recov. 51 (n) 87 (n) Wadhwa (RCT) 72% 0.28 [0.09-0.85] progression 4/74 9/46 Wadhwa (RCT) 49% 0.51 [0.27-0.95] no disch. 13/74 16/46 Wadhwa (RCT) 18% 0.82 [0.67-1.00] recov. time 74 (n) 46 (n) Holt -129% 2.29 [1.59-3.32] death/ICU 16/31 148/658 Jeon 77% 0.23 [0.08-0.64] cases case control MacFadden 7% 0.93 [0.88-0.98] cases n/a n/a Cousins (PSM) 81% 0.19 [0.06-0.65] ventilation 731 (n) 731 (n) Cousins (PSM) 66% 0.34 [0.17-0.68] ICU 731 (n) 731 (n) Cousins (PSM) 18% 0.82 [0.71-0.93] death 390/12,504 479/12,504 Cousins (PSM) 12% 0.88 [0.79-0.99] death 521/16,324 592/16,324 Cousins (PSM) 15% 0.85 [0.77-0.94] death 671/20,690 783/20,690 Cousins (PSM) 17% 0.83 [0.77-0.91] ventilation 936/12,504 1,118/12,504 Cousins (PSM) 17% 0.83 [0.77-0.89] ventilation 1,212/16,324 1,459/16,324 Cousins (PSM) 10% 0.90 [0.84-0.95] ventilation 1,524/20,690 1,701/20,690 Spironolactone COVID-19 outcomes c19 early1 CT: study uses combined treatment Favors spironolactone Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
